keyword
MENU ▼
Read by QxMD icon Read
search

(lung cancer) and (immunotherapy)

keyword
https://www.readbyqxmd.com/read/29332322/tumor-immunology-and-immune-checkpoint-inhibitors-in-non-small-cell-lung-cancer
#1
REVIEW
Chi Young Jung, Scott J Antonia
Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths worldwide. Although progress in the treatment of advanced non-small cell lung cancer (NSCLC) has been made over the past decade, the 5-year survival rate in patients with lung cancer remains only 10%-20%. Obviously, new therapeutic options are required for patients with advanced NSCLC and unmet medical needs. Cancer immunotherapy is an evolving treatment modality that uses a patient's own immune systems to fight cancer...
January 2018: Tuberculosis and Respiratory Diseases
https://www.readbyqxmd.com/read/29331646/progress-in-the-management-of-advanced-thoracic-malignancies-in-2017
#2
REVIEW
Roberto Ferrara, Laura Mezquita, Benjamin Besse
The treatment paradigm of non-small cell lung cancer (NSCLC) underwent a major revolution during the course of 2017. Immune checkpoint inhibitors (ICIs) brought remarkable improvements in response and overall survival (OS) both in unselected pretreated patients and in untreated patients with PD-L1 expression ≥50%. Furthermore, compelling preliminary results were reported for new combinations of anti-PD-1/PD-L1 agents with chemotherapy or anti-CTLA4 inhibitors. The success of the ICIs appeared to extend to patients with small cell lung cancer (SCLC), mesothelioma or thymic tumors...
January 10, 2018: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29330759/-autoimmune-reactions-to-immune-checkpoint-inhibitors
#3
REVIEW
W Pönisch, R Alten, C Baerwald
Immune checkpoint inhibitors (ICI) have dramatically changed the face of cancer treatment and are gaining in importance. The ICIs have now been approved for the treatment of advanced cancers, including melanoma, non-small-cell and small cell lung cancers, renal cell carcinoma, Hodgkin's lymphoma, head and neck cancers and urothelial carcinoma and further indications are to be expected. The organs most affected by an autoimmune reaction are the intestines, the musculoskeletal system, skin, endocrine organs, the liver and the lungs...
October 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/29330207/early-assessment-of-lung-cancer-immunotherapy-response-via-circulating-tumor-dna
#4
Sarah B Goldberg, Azeet Narayan, Adam J Kole, Roy H Decker, Jimmitti Teysir, Nicholas J Carriero, Angela Lee, Roxanne Nemati, Sameer K Nath, Shrikant M Mane, Yanhong Deng, Nitin Sukumar, Daniel Zelterman, Daniel J Boffa, Katerina Politi, Scott Gettinger, Lynn D Wilson, Roy S Herbst, Abhijit A Patel
PURPOSE: Decisions to continue or suspend therapy with immune checkpoint inhibitors are commonly guided by tumor dynamics seen on serial imaging.  However, immunotherapy responses are uniquely challenging to interpret because tumors often shrink slowly or can appear transiently enlarged due to inflammation.  We hypothesized that monitoring tumor cell death in real-time by quantifying changes in circulating tumor DNA (ctDNA) levels could enable early assessment of immunotherapy efficacy...
January 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29329112/master-protocols-in-lung-cancer-experience-from-lung-master-protocol
#5
Vincent K Lam, Vassiliki Papadimitrakopoulou
PURPOSE OF REVIEW: Contemporary advances in the understanding of the molecular and immunologic basis of metastatic lung cancer have firmly changed its treatment paradigm to a personalized, biomarker-driven approach. However, the majority of lung-cancer patients [especially lung squamous cell carcinoma (LUSC)] still do not have effective targeted therapeutic options. Master protocols, such as Lung-MAP, represent an innovative clinical trial approach designed to accelerate evaluation of novel biomarker-driven therapies...
January 10, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29322798/pd-l1-expression-can-be-regarded-as-prognostic-factor-for-survival-of-non-small-cell-lung-cancer-patients-after-chemoradiotherapy
#6
M Vrankar, M Zwitter, I Kern, K Stanic
Inoperable locally advanced non-small cell lung cancer (LA NSCLC) is treated with concurrent or sequential chemotherapy (ChT) and radiation therapy (RT). Survival rates with this treatment remains poor, reported 5-year survival is about 15%. New treatment strategies, including immunotherapy with programmed death ligand-1 (PD-L1) check point inhibitors are being investigated. The clinical significance of PD-L1 expression in tumor samples from patients with inoperable LA NSCLC who underwent concurrent chemoradiotherapy (CRT) in our institution between 2005 and 2010 was evaluated...
2018: Neoplasma
https://www.readbyqxmd.com/read/29313655/lung-cancer-management
#7
Timothy F Mott
Lung cancer management that is individualized for age, comorbidities, cancer type, cancer stage, and patient preference has long been a cornerstone of management. New to this realm of individualized management are the emerging biologic therapies, immunotherapies, and targeted therapies for non-small-cell lung cancer provided by advances in genetics and molecular medicine. These techniques have led to a new field of precision medicine based on the unique molecular characteristics of a specific patient and the specific cancer...
January 2018: FP Essentials
https://www.readbyqxmd.com/read/29306075/fasn-tgf-%C3%AE-1-pd-l1-axis-contributes-to-the-development-of-resistance-to-nk-cell-cytotoxicity-of-cisplatin-resistant-lung-cancer-cells
#8
MingJing Shen, Ying Tsai, Rongying Zhu, Peter C Keng, Yongbing Chen, Yuhchyau Chen, Soo Ok Lee
Cisplatin remains the most effective therapy for non-small cell lung cancer (NSCLC). We previously have found cisplatin-resistant lung cancer cells (A549CisR and H157CisR) were more resistant to natural killer (NK) cell-mediated cytotoxicity than parental cells. We also discovered that fatty acid synthase (FASN) levels in cisplatin-resistant cells were significantly higher than parental cells. To reveal whether a link exists between the up-regulated FASN levels and higher resistance to NK cell cytotoxicity, we performed inhibition studies using a FASN inhibitor and applied the FASN knockdown approach...
January 3, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29303787/supportive-care-in-the-era-of-immunotherapies-for-advanced-non-small-cell-lung-cancer
#9
Gil Awada, Jean Klastersky
PURPOSE OF REVIEW: The therapeutic armamentarium for advanced non-small-cell lung cancer has evolved considerably over the past years. Immune checkpoint inhibitors targeting programmed cell death-1 such as pembrolizumab and nivolumab or programmed cell death ligand 1 such as atezolizumab, durvalumab and avelumab have shown favorable efficacy results in this patient population in the first-line and second-line setting. These immunotherapies are associated with a distinct toxicity profile based on autoimmune organ toxicity which is a new challenge for supportive care during treatment with these drugs...
January 4, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29303290/-non-small-cell-lung-cancer
#10
Jana Skřičková, Bohdan Kadlec, Ondřej Venclíček
Non-small cell lung cancer (NSCLC) represents 80 % of diseases considering all patients with lung cancer. NSCLC comprises all histological types except for the small cell cancer. The treatment is chosen based on a clinical stage, morphological diagnosis and performance status of patients. In the low clinical stages a surgical solution is indicated. An alternative is radiotherapy. In some cases adjuvant treatment is indicated. In the locally advanced and metastatic stages chemotherapy and biological therapies are available and in recent time also immunotherapy is used...
2018: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29303289/-small-cell-lung-cancer-epidemiology-diagnostics-and-therapy
#11
Miloš Pešek, Jan Mužík
Authors present actual overview of information on diagnostic and therapeutic procedures in small-cell lung cancer (SCLC). This highly aggressive type of lung cancer is diagnosed in 14.8 % of Czech lung cancer patients. Vast majority of those patients (87 %) suffer from advanced and metastatic disease in the time of diagnosis. In this issue are presented prognostic factors, staging diagnostic procedures and therapeutic recommendations. The backbone of actual SCLC treatment is combined chemotherapy and radiotherapy and less frequently, carefully in selected cases, surgical procedures...
2018: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29302641/cancer-immunotherapy-in-patients-with-new-or-recurrent-malignancies-after-liver-transplantation
#12
REVIEW
Mengqi Liu, Wenzhi Guo, Shuijun Zhang
Cancer immunotherapy, as a new treatment modality, has been shown to be effective, especially in metastatic melanoma and lung cancer. Organ transplantation can be a life-saving procedure for patients with end-stage diseases of lung, heart, kidney and liver. While ironically, as improvements in organ transplantation have extended patients' lives, new or recurrent postsurgical malignancies have become an increasing threat to their long-term survival, especially in patients after liver transplantation due to hepatocellular carcinoma...
December 2017: International Journal of Surgery. Oncology
https://www.readbyqxmd.com/read/29302251/immunotherapy-for-non-small-cell-lung-cancer-current-status-and-future-obstacles
#13
REVIEW
Ju Hwan Cho
Lung cancer is one of the leading causes of death worldwide. There are 2 major subtypes of lung cancer, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Studies show that NSCLC is the more prevalent type of lung cancer that accounts for approximately 80%-85% of cases. Although, various treatment methods, such as chemotherapy, surgery, and radiation therapy have been used to treat lung cancer patients, there is an emergent need to develop more effective approaches to deal with advanced stages of tumors...
December 2017: Immune Network
https://www.readbyqxmd.com/read/29299428/dr-giannis-mountzios-immunotherapy-an-earthquake-in-the-treatment-of-advanced-lung-cancer
#14
Nikki Ling
No abstract text is available yet for this article.
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29299419/keynote-028-how-do-we-use-immunotherapy-in-small-cell-lung-cancer
#15
EDITORIAL
Jose M Pacheco, D Ross Camidge
No abstract text is available yet for this article.
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29299415/small-cell-lung-cancer-in-the-era-of-immunotherapy
#16
EDITORIAL
Margarita Majem, Charles M Rudin
No abstract text is available yet for this article.
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29290777/classifying-non-small-cell-lung-cancer-by-status-of-programmed-cell-death-ligand-1-and-tumor-infiltrating-lymphocytes-on-tumor-cells
#17
Shaohua Cui, Lili Dong, Jialin Qian, Lin Ye, Liyan Jiang
Purpose: To explore the possible correlation between programmed death ligand 1 (PD-L1)/tumor-infiltrating lymphocytes (TIL) status and clinical factors in non-small cell lung (NSCLC). Materials and Methods: A total of 126 surgical NSCLC samples with stage I to IIIA were retrospectively collected and analyzed. Immunohistochemistry (IHC) assays were used to detect PD-L1 protein expression. PD-L1 positivity on tumor cells was defined by positive tumor cell (TC) percentage using 5% cutoff value. Results: Thirty-seven patients (29...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29290269/how-does-autoimmune-disease-impact-treatment-and-outcomes-among-patients-with-lung-cancer-a-national-seer-medicare-analysis
#18
Saad A Khan, Sandi L Pruitt, Lei Xuan, Una Makris, David E Gerber
BACKGROUND: The advent of cancer immunotherapy has made autoimmune disease in oncology populations clinically important. We analyzed the association of autoimmune disease with treatment and outcomes among lung cancer patients. METHODS: Using linked Surveillance Epidemiology and End Results (SEER)-Medicare data, we identified lung cancer patients diagnosed between 1992 and 2009 with autoimmune diseases. We recorded number and timing of autoimmune disease diagnoses, lung cancer treatment, and markers of healthcare utilization including emergency department visits, hospitalizations, and outpatient visits...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290267/comparative-effectiveness-of-immune-checkpoint-inhibitors-for-previously-treated-advanced-non-small-cell-lung-cancer-a-systematic-review-and-network-meta-analysis-of-3024-participants
#19
Pui San Tan, Pedro Aguiar, Benjamin Haaland, Gilberto Lopes
INTRODUCTION: Role of PD-L1 expression to guide immunotherapies in previously treated advanced NSCLC remains unclear and there is a lack of data comparing immune checkpoint inhibitors (ICIs) with each other. This network meta-analysis (NMA) aims to compare survival with ICIs to docetaxel and perform indirect comparisons between ICIs in the PD-L1 unselected population and by PD-L1 expression levels. METHODS: PubMed was searched and study screening was performed by two independent reviewers...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29282718/multispectral-imaging-for-quantitative-and-compartment-specific-immune-infiltrates-reveals-distinct-immune-profiles-that-classify-lung-cancer-patients
#20
Artur Mezheyeuski, Christian Holst Bergsland, Max Backman, Dijana Djureinovic, Tobias Sjöblom, Jarle Bruun, Patrick Micke
Semiquantitative assessment of immune markers by immunohistochemistry (IHC) has significant limitations for describing the diversity of the immune response in cancer. Therefore we evaluated a fluorescence-based multiplexed IHC method in combination with a multispectral imaging system to quantify immune infiltrates in situ in the environment of non-small cell lung cancer (NSCLC). A tissue microarray including 57 non-small cell lung cancer (NSCLC) cases was stained with antibodies to CD8, CD20, CD4, FOXP3, CD45RO and for pan-cytokeratin and immune cells were quantified in epithelial and stroma compartments...
December 27, 2017: Journal of Pathology
keyword
keyword
91240
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"